INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Oncology / Health Desk

Mushrooms and cancer: a pooled signal shaped by case-control studies

A 17-study review found lower cancer risk with higher mushroom intake, but most included studies were case-control designs.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

What the review brought together

The mushroom review assembled 17 observational studies published within a search window running from January 1966 through October 2020. Eligible studies compared at least two categories of mushroom intake and reported a relative risk, hazard ratio, or odds ratio with a confidence interval. This was a synthesis of dietary associations, not a trial assigning people to eat mushrooms. That distinction frames the entire result: the analysis asked whether people reporting different intakes had different cancer risks. Its scope was cancer at any site, with additional analyses examining breast cancer and other cancer groupings rather than a single uniform diagnosis.

Ba DM, Ssentongo P, Beelman RB, Muscat J et al.. Advances in nutrition (Bethesda, Md.), 2021. PMID 33724299 · DOI

The overall estimate and its boundaries

Across all 17 studies, the pooled relative risk comparing the highest with the lowest mushroom consumption groups was 0.66, with a 95% confidence interval of 0.55 to 0.78. The review used random-effects models to combine the estimates. This is a relative comparison between intake categories, not an absolute estimate of how many cancers a mushroom dish would prevent. The abstract also reports evidence of a nonlinear dose-response association for total cancer, based on seven studies, with a nonlinearity P value of 0.001. It does not establish a universal serving target or a randomized cancer-prevention effect.

Ba DM, Ssentongo P, Beelman RB, Muscat J et al.. Advances in nutrition (Bethesda, Md.), 2021. PMID 33724299 · DOI

Breast cancer was the clearest site-specific signal

For breast cancer, the highest-versus-lowest intake comparison produced a pooled relative risk of 0.65, with a 95% confidence interval of 0.52 to 0.81, across ten studies. A broader nonbreast cancer grouping gave a relative risk of 0.80, with a confidence interval of 0.66 to 0.97, across thirteen studies. Those groupings should not be mistaken for identical evidence at every cancer site. When the researchers examined individual cancer sites, only breast cancer showed a statistically significant association. The authors noted that the small number of studies for other cancers could help explain that difference in the findings.

Ba DM, Ssentongo P, Beelman RB, Muscat J et al.. Advances in nutrition (Bethesda, Md.), 2021. PMID 33724299 · DOI

Why the study design matters

Eleven of the 17 included studies used case-control designs. The abstract explicitly identifies possible recall bias and selection bias in those studies as limitations. It also notes substantial variation in the adjustment factors used in the original studies' final models. These are reasons to describe the pooled result as an association rather than a demonstrated protective effect. The authors suggest a possible protective role for mushrooms, particularly in relation to breast cancer, but their evidence remains observational. A careful takeaway preserves both parts of that conclusion: a notable lower-risk signal and important uncertainty about whether mushrooms themselves caused it.

Ba DM, Ssentongo P, Beelman RB, Muscat J et al.. Advances in nutrition (Bethesda, Md.), 2021. PMID 33724299 · DOI